Tyme Technologies, Inc. Common Stock (TYME)

TYME was delisted on the 16th of September, 2022.

• Market cap: $53.5M
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.

Employees: 13